/ 2 items

#EXEL↓

KURA/ 04/17/2026 · 7:14 AM

Kura Oncology Stock Surges as Darlifarib + Cabozantinib Shows Strong Results in Tough Kidney Cancer Cases

Kura Oncology’s combo drug shrank kidney tumors in early trial, controlled cancer in most patients, stock jumped.

EXEL/ 10/20/2025 · 4:28 PM

William Blair Maintains Buy Rating on Exelixis Following Positive Cancer Trial Results, Despite Safety Concerns

William Blair analyst Andy Hsieh reaffirms Buy rating on EXEL stock after Phase III trial shows zanzalintinib combination therapy improves survival in metastatic colorectal cancer patients.